In 2021, clinical trials reported the promising effects of incretins and a new class of dual glucagon-like peptide 1–glucose-dependent insulinotropic peptide receptor agonists in preventing and treating type 2 diabetes mellitus and obesity. These ‘twincretins’ will transform the prevention of obesity and type 2 diabetes mellitus and the care of people with these conditions.
Once weekly semaglutide, the most potent GLP1 receptor agonist, was safe and effective for treating obesity, achieving average weight loss of 15% among individuals without any form of diabetes mellitus4.
In the SURPASS-1 trial, tirzepatide (a new dual GIP–GLP1 receptor agonist based on the native GIP sequence) was associated with up to 2% reduction in HbA1c and a dose-dependent reduction in body weight of 7–9 kg in patients with type 2 diabetes mellitus6.
Tirzepatide was superior to semaglutide in head-to-head comparisons in reducing HbA1c and body weight, with a similar incidence of gastrointestinal adverse effects7.
Tirzepatide was also superior to insulin degludec in reducing HbA1c and body weight, with a lower risk of hypoglycaemia8.
This is a preview of subscription content, access via your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 per month
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Chan, J. C. N. et al. The Lancet Commission on diabetes: using data to transform diabetes care and patient lives. Lancet 396, 2019–2082 (2021).
Nauck, M. A., Bartels, E., Orskov, C., Ebert, R. & Creutzfeldt, W. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J. Clin. Endocrinol. Metab. 76, 912–917 (1993).
Finan, B. et al. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci. Transl. Med. 5, 209ra151 (2013).
Wilding, J. P. H. et al. Once-weekly semaglutide in adults with overweight or obesity. N. Engl. J. Med 384, 989–1002 (2021).
Min, T. & Bain, S. C. The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: the SURPASS clinical trials. Diabetes Ther 12, 143–157 (2021).
Rosenstock, J. et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet 398, 143–155 (2021).
Frías, J. P. et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N. Engl. J. Med. 385, 503–515 (2021).
Ludvik, B. et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet 398, 583–598 (2021).
Wilson, J. M. et al. The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: a post hoc analysis. Diabetes Obes. Metab. https://doi.org/10.1111/dom.14553 (2021).
Chung, W. K. et al. Precision medicine in diabetes: a consensus report from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 63, 1671–1693 (2020).
J.C.N.C. has received speaker fees and research grants through institutions from Applied Therapeutics, Astra Zeneca, Bayer, Boehringer Ingelheim, Celltrion, Hua Medicine, Lee Powder, Lilly, Merck Sharpe Dohme, Merck Serono, Pfizer, Sanofi, Servier and Virtus Pharmaceutical. E.C. has received speaker fees from Sanofi, Novartis and institutional research support from Sanofi, Medtronic Diabetes and Powder Pharmaceuticals Inc.
Rights and permissions
About this article
Cite this article
Chow, E., Chan, J.C.N. The emerging role of incretins and twincretins. Nat Rev Endocrinol 18, 73–74 (2022). https://doi.org/10.1038/s41574-021-00607-w